Published in Health Business Week, December 31st, 2004
Douglas has been appointed to fill a vacancy on the board of directors with a term ending at the next annual stockholders meeting, at which time he will be considered for election for a full term.
Until his recent retirement, Douglas was executive vice president, drug innovation & approval and chief scientific officer of Aventis Pharma, AG, where he oversaw Aventis' worldwide pharmaceutical research and development activities and was a member of the board of management of Aventis, SA.
Douglas commented, "Gene Logic's emphasis on providing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.